Ricevi le ultime notizie sulle azioni Cassava Sciences con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di SAVA

Ultime notizie per

Cassava Sciences

Cassava Sciences Inc

Cassava Sciences Inc Warrants (15/11/2024)

Savara Inc

SAVANNAH RESOURCES PLC by SAVANNAH RESOURCES PLC

Savannah Resources PLC

Savaria Corp

SAVANNAH GOLDFIELDS LTD by SAVANNAH GOLDFIELDS LTD

SAVANNAH ENERGY PLC by Savannah Energy Plc

Savannah Energy PLC

Aardvark Therapeutics, Inc. - Common Stock

Aardvark Therapeutics

Aurora Cannabis

Aclaris Therapeutics, Inc. - Common Stock

Aclaris Therapeutics

Anebulo Pharmaceuticals, Inc. - Common Stock

Anebulo Pharmaceuticals

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Context Therapeutics

Cardiol Therapeutics Inc. - Class A Common Shares

Cardiol Therapeutics

Journey Medical Corporation - Common Stock

Journey Medical

Vyome Holdings

High Tide

ImageneBio

Incannex Healthcare

MediWound

Milestone Pharmaceuticals Inc. - Common Shares

Milestone Pharmaceuticals

NeOnc Technologies Holdings, Inc. - Common Stock

NeOnc Technologies Hldgs

Organigram Global

Oramed Pharmaceuticals Inc. - Common Stock

Oramed Pharmaceuticals

Pliant Therapeutics

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Hldgs

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics

Scilex Holding

Sol-Gel Technologies Ltd. - Ordinary Shares

Sol-Gel Technologies

China SXT Pharmaceuticals, Inc. - Common Stock

China SXT Pharmaceuticals

Turn Therapeutics

Zhengye Biotechnology Holding Limited - Ordinary Shares

Zhengye Biotechnology

Cassava Sciences (SAVA) Previsione

Notizie

Utili

Quote.Nav.option-chain

Dividendi

Valutazioni degli analisti

Insider trading

Vendite allo scoperto

Commerci governativi

Rapporto azionario

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.

Comments

Cassava Sciences Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO